The biotech beat Wall Street estimates. But there's still a big unanswered question.
News & Analysis: Nektar Therapeutics
An analyst downgrade is only adding to the company's woes.
Manufacturing issues plague the start-up.
The biotech continues to feel the repercussions from news announced last week.
The biotech's manufacturing problems with a key experimental drug and uncertainty about a major partnership are rattling investors.
The company can't seem to sustain any momentum.
A drug candidate was oh-so-close to a regulatory decision, but next month's meeting has been delayed indefinitely.
Was last month a turning point in a not-so-good year for shareholders?
Promising data suggest the company might be able to raise the bar in melanoma treatments.
The biotech company clawed back some of 2018's losses in the first month of the new year.
Last year started out with a bang, but the excitement didn't last very long.